Inicio / Hematología / Abstracts de hematología / Tyrosine kinase inhibitor…

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

0 / 5 (0 votos)
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

American Journal of Hematology

Fecha de publicación: 5 october 2018

DOI: https://doi.org/10.1002/ajh.25306

Autores: Rüdiger Hehlmann, Jorge E. Cortes, Teresa Zyczynski, Carlo Gambacorti‐Passerini, Stuart L. Goldberg, Michael J. Mauro, Mauricette Michallet, Bengt Simonsson, Loretta A. Williams, et al.  

Background: SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor (TKI) use and management patterns in patients with chronic phase‐chronic myeloid leukemia in the US and Europe in routine clinical practice. 

Seguir leyendo

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.